Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
Status:
Completed
Trial end date:
2019-06-14
Target enrollment:
Participant gender:
Summary
This study is being conducted in order to assess the need for dose adjustment for elafibranor
in patients with hepatic impairment. Pharmacokinetic parameters of elafibranor and its active
metabolite (GFT1007) will be compared in hepatic impaired patients (mild, moderate and severe
according to Child-Pugh categories) versus healthy participants after a single oral
administration of elafibranor 120 mg.